Thomas Hughes

Thomas Hughes

Company: Navitor

Job title: Chief Executive Officer


Examine Polycystic Kidney Disease as a First Indication for Development of the mTORC1-selective Rapamycin Analog NV-20494 2:45 pm

Explore Kidney cyst formation and its relationship to mTORC1 dysregulation Overview of prior experience in polycystic kidney disease with rapamycin and everolimus, and mechanistic considerations related to the importance of mTORC1 selectivity Investigate approaches to gathering insight regarding impact of mTORC1 inhibition on endpoints of relevance to longevityRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.